Evidence map›Paper›PMID 36706324›Full record

ArticleACS synthetic biology2023

Increasing the Scalability of Toxin-Intein Orthogonal Combinations.

Rocío López-Igual, Pedro Dorado-Morales, Didier Mazel

Open access · hybridAbstract read
In one paragraph

Article in ACS synthetic biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Rocío López-IgualInstitut Pasteur, Université de Paris, Unité Plasticité du Génome Bactérien, et CNRS, UMR3525, 28 Rue du Dr Roux, F-75015 Paris, France.ORCID 0000-0002-2369-1583
Pedro Dorado-MoralesInstitut Pasteur, Université de Paris, Unité Plasticité du Génome Bactérien, et CNRS, UMR3525, 28 Rue du Dr Roux, F-75015 Paris, France.ORCID 0000-0001-5760-1999
Didier MazelInstitut Pasteur, Université de Paris, Unité Plasticité du Génome Bactérien, et CNRS, UMR3525, 28 Rue du Dr Roux, F-75015 Paris, France.ORCID 0000-0001-6482-6002
Centre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inteins are proteins embedded into host proteins from which they are excised in an autocatalytic reaction. Specifically, split inteins are separated into two independent fragments that reconstitute the host protein during the catalytic process. We recently developed a novel strategy for the specific killing of pathogenic and antibiotic resistant bacteria based on toxin-intein combinations. Bacterial type II toxin-antitoxin systems are protein modules in which the toxin can provoke cell death whereas the antitoxin inhibits toxin activity. Although our previous system was based on a split intein (iDnaE) and the CcdB toxin, we demonstrated that iDnaE is able to reconstitute four different toxins. To expand the applicability of our system by widening the repertoire of toxin-intein combinations for complex set-ups, we introduced a second intein, iDnaX, which was artificially split. We demonstrate that iDnaX is able to reconstitute the four toxins, and we manage to reduce its scar size to facilitate their use. In addition, we prove the orthogonality of both inteins (iDnaE and iDnaX) through a toxin reconstitution assay, thus opening the possibility for complex set-ups based on these toxin-intein modules. This could be used to develop specific antimicrobial and other biotechnological applications.

Indexed as

InteinsProtein SplicingProteinsProteinsbacterial killinginteinsmicrobial synthetic biologyprotein splicingtoxin−antitoxin systems

Identifiers

PMID36706324
PMCPMC9942249
OpenAlexW4318307951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.